Anaplastic Astrocytoma Treatment Market Industrial Progress 2017 to 2022
Astrocytoma is a medical condition that develops from astrocytes, a star-shaped brain cells. The disease has been categorized into four different groups based on reproduction rate of the cell, and its capability to spread in nearby tissues. Grades I and Grades II astrocytomas are non-malignant, and can be referred to as low grade. However, Grades III and Grades IV are malignant, and has the capacity to spread quickly. With time, lower grade astrocytoma can change to high grade astrocytoma. Grade III astrocytomas are also called as anaplastic astrocytomas. Anaplastic Astrocytoma is a rare medical condition, and can be divided into two categories – IDH-mutant, IDH-wildtype. IDH1 is a gene that encodes for a metabolic enzyme called isocitrate dehydrogenase 1. According to American Brain Tumor Association, about 25,000 new cases of primary malignant brain tumors were diagnosed in the U.S. in 2016. Moreover, about 50% of gliomas are glioblastomas. Occurrence of anaplastic astrocytomas is more common in adults compared to children, according to American Brain Tumor Association (ABTA). The ABTA estimates that anaplastic astrocytomas in people aged 30-35 years accounted for 17% of primary malignant brain tumors, however, only 9% of tumor in children are glioblastomas.
Get The Holistic SAMPLE With Research Methodology: https://www.coherentmarketinsights.com/insight/request-sample/1525
Anaplastic Astrocytoma Treatment Market: Driver
Increasing number of drug candidate in pipeline, which may receive approval over the forecast period is expected to drive growth of the global anaplastic astrocytoma treatment market. Currently, there is only a drug, temozolomide (Temodar), approved by U.S. FDA for Anaplastic Astrocytoma. Temodar is an alkylating agent that has been approved for both conditions, newly diagnosed patients as well as refractory anaplastic astrocytoma patients, who have witnessed disease progression in spite of taking drug containing nitrosourea and procarbazine. However, there are multiple products in pipeline for the treatment of anaplastic astrocytoma. For instance, DCC-2618, a drug candidate developed by Deciphera Pharmaceuticals, Inc. is currently in Phase 1 clinical trials. The drug has also been granted orphan drug designation for the treatment of anaplastic astrocytoma and glioblastoma multiforme (GBM) in September 2017. Moreover, an experimental drug PAC-1 was cleared for the clinical trial of patients with anaplastic astrocytoma in November 2017. The drug candidate is being developed by Vanquish Oncology, Inc. The trial will determine if the drug candidate is safe to use in combination with a standard chemotherapy drug, temozolomide.
Click To Continue Reading On Anaplastic Astrocytoma Treatment Market
You may be interested
Tinnitus Management Market predicts rise in demand by 2026Albert R - August 16, 2018
Tinnitus Management Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share,…
Body Composition Analyzers Market Trends Estimates High Demand by 2026Albert R - August 16, 2018
Body Composition Analyzers Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market…
Alveolar Rhabdomyosarcoma Treatment Market Trends Estimates High Demand by 2026Albert R - August 16, 2018
Alveolar Rhabdomyosarcoma Treatment Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market…